News Releases

- 71 patients dosed in the potentially pivotal Phase 2 clinical study of firicabtagene autoleucel ( firi-cel); Interim analysis results expected to be reported in 1H’25 - - IND application for CRG-023, CARGO’s tri-specific CAR T, cleared by the FDA; Phase 1 study enrollment expected to initiate